JP2000511421A5 - - Google Patents

Download PDF

Info

Publication number
JP2000511421A5
JP2000511421A5 JP1997542853A JP54285397A JP2000511421A5 JP 2000511421 A5 JP2000511421 A5 JP 2000511421A5 JP 1997542853 A JP1997542853 A JP 1997542853A JP 54285397 A JP54285397 A JP 54285397A JP 2000511421 A5 JP2000511421 A5 JP 2000511421A5
Authority
JP
Japan
Prior art keywords
cells
cancer
antibody
antigen
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1997542853A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000511421A (ja
JP4124486B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/008962 external-priority patent/WO1997044461A2/en
Publication of JP2000511421A publication Critical patent/JP2000511421A/ja
Publication of JP2000511421A5 publication Critical patent/JP2000511421A5/ja
Application granted granted Critical
Publication of JP4124486B2 publication Critical patent/JP4124486B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP54285397A 1996-05-22 1997-05-22 ガン細胞を特異的に検出する抗原結合フラグメント、このフラグメントをコードするヌクレオチド、ならびにガンの予防および検出のためのその使用 Expired - Fee Related JP4124486B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65744996A 1996-05-22 1996-05-22
US08/657,449 1996-05-22
PCT/US1997/008962 WO1997044461A2 (en) 1996-05-22 1997-05-22 Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007248260A Division JP2008099684A (ja) 1996-05-22 2007-09-25 ガン細胞を特異的に検出する抗原結合フラグメント、このフラグメントをコードするヌクレオチド、ならびにガンの予防および検出のためのその使用

Publications (3)

Publication Number Publication Date
JP2000511421A JP2000511421A (ja) 2000-09-05
JP2000511421A5 true JP2000511421A5 (enExample) 2007-12-06
JP4124486B2 JP4124486B2 (ja) 2008-07-23

Family

ID=24637247

Family Applications (2)

Application Number Title Priority Date Filing Date
JP54285397A Expired - Fee Related JP4124486B2 (ja) 1996-05-22 1997-05-22 ガン細胞を特異的に検出する抗原結合フラグメント、このフラグメントをコードするヌクレオチド、ならびにガンの予防および検出のためのその使用
JP2007248260A Withdrawn JP2008099684A (ja) 1996-05-22 2007-09-25 ガン細胞を特異的に検出する抗原結合フラグメント、このフラグメントをコードするヌクレオチド、ならびにガンの予防および検出のためのその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2007248260A Withdrawn JP2008099684A (ja) 1996-05-22 2007-09-25 ガン細胞を特異的に検出する抗原結合フラグメント、このフラグメントをコードするヌクレオチド、ならびにガンの予防および検出のためのその使用

Country Status (15)

Country Link
US (3) US6207153B1 (enExample)
EP (1) EP0912738B1 (enExample)
JP (2) JP4124486B2 (enExample)
KR (1) KR20000015893A (enExample)
CN (1) CN1201005C (enExample)
AT (1) ATE403001T1 (enExample)
AU (1) AU725238B2 (enExample)
BR (1) BR9710811A (enExample)
DE (1) DE69738868D1 (enExample)
DK (1) DK0912738T3 (enExample)
ES (1) ES2312177T3 (enExample)
IL (1) IL127193A (enExample)
NO (1) NO985150L (enExample)
NZ (1) NZ332566A (enExample)
WO (1) WO1997044461A2 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000015893A (ko) * 1996-05-22 2000-03-15 댄 마이클 특이적으로 암세포를 검출하는 항원 결합 단편, 상기 단편을 코딩하는 뉴클레오티드 및 암의 예방 및 검출에 사용되는 이들의 용도
US20020122807A1 (en) * 1998-07-07 2002-09-05 Dan Michael D. Antigen binding fragments, designated 4B5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
EP1047457A2 (en) * 1998-01-16 2000-11-02 MCA Development B.V. USE OF RADIOLABELED MONOCLONAL IgM IN THERAPY FOR CANCER AND AUTOIMMUNE DISEASE
DE69942782D1 (de) 1998-11-27 2010-10-28 Ucb Sa Zusammensetzungen und Verfahren zur Erhöhung der Knochenmineralisierung
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
WO2001040292A1 (en) * 1998-11-27 2001-06-07 Novopharm Biotech Inc. Antigen-binding fragments specific for tumor associated antigens
US20090123470A1 (en) * 2001-03-26 2009-05-14 The Macfarlane Burnet Istitute For Medical Research And Public Health Ltd. Antibodies Against Cancer
AUPR395801A0 (en) * 2001-03-26 2001-04-26 Austin Research Institute, The Antibodies against cancer
HUP0501113A3 (en) * 2001-04-26 2007-12-28 Biogen Idec Inc Cripto blocking antibodies and uses thereof
US7582299B2 (en) * 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
AU2002314794A1 (en) * 2001-05-23 2002-12-03 New York University Detection of alzheimer's amyloid by magnetic resonance imaging
US7115716B2 (en) * 2001-11-19 2006-10-03 Eli Lilly And Company Tumor specific monoclonal antibodies
WO2003044036A1 (en) * 2001-11-19 2003-05-30 Applied Molecular Evolution, Inc. Tumor specific monoclonal antibodies
WO2003087763A2 (en) 2002-04-03 2003-10-23 Celltech R & D, Inc. Association of polymorphisms in the sost gene region with bone mineral density
US7041309B2 (en) * 2002-06-13 2006-05-09 Neuropro Technologies, Inc. Spinal fusion using an HMG-CoA reductase inhibitor
US8029803B2 (en) * 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8025873B2 (en) 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US20040176577A1 (en) * 2002-09-10 2004-09-09 Eva Rojer Immunoassays for specific determination of SCCA isoforms
US7285269B2 (en) * 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
EP1636270B1 (en) 2003-06-16 2016-07-20 UCB Pharma S.A. Antibodies specific for sclerostin and methods for increasing bone mineralization
US8007805B2 (en) * 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
US20050220796A1 (en) * 2004-03-31 2005-10-06 Dynan William S Compositions and methods for modulating DNA repair
IL161673A0 (en) * 2004-04-29 2004-09-27 Applied Research Systems Compositions and methods for therapy of chemotherapy-induced neuropathy
EP2311880A3 (en) 2005-01-05 2011-07-27 Biogen Idec MA Inc. Cripto binding molecules
ITMI20050739A1 (it) * 2005-04-22 2006-10-23 Effebi Spa Piastrina di connsessione valvola-attuatore
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
TW200732346A (en) * 2005-10-13 2007-09-01 Virexx Medical Corp Chimeric hepatitis C virus antigens for eliciting an immune response
TW200722436A (en) * 2005-10-21 2007-06-16 Hoffmann La Roche A peptide-immunoglobulin-conjugate
CN104072611A (zh) * 2005-12-21 2014-10-01 维文蒂阿生物公司 与癌症相关的新抗原
US20100036091A1 (en) * 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
WO2008133722A2 (en) * 2006-11-10 2008-11-06 Ucb Pharma S.A. Anti human sclerostin antibodies
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
EP2628486A3 (en) * 2007-12-14 2013-10-30 Amgen, Inc. Method for treating bone fracture with anti-sclerostin antibodies
US20110110772A1 (en) * 2009-11-11 2011-05-12 Arrell Douglas J Turbine Engine Components with Near Surface Cooling Channels and Methods of Making the Same
DE102010005485B4 (de) 2010-01-23 2021-11-25 Dr. Ing. H.C. F. Porsche Aktiengesellschaft Trägerteil
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
US9133272B2 (en) 2011-03-01 2015-09-15 Amgen Inc. Bispecific binding agents
JP2014511842A (ja) 2011-03-25 2014-05-19 アムジエン・インコーポレーテツド 抗スクレロスチン抗体結晶およびその製剤
DK2739311T3 (en) 2011-08-04 2018-04-23 Amgen Inc Method of treating bone slit defects
EA036740B1 (ru) 2011-12-28 2020-12-15 Эмджен Инк. Способ увеличения высоты альвеолярного отростка посредством применения антител к склеростину
WO2014006100A1 (en) 2012-07-05 2014-01-09 Ucb Pharma S.A. Treatment for bone diseases
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
PE20160533A1 (es) 2013-03-14 2016-06-09 Bayer Healthcare Llc Anticuerpos monoclonales contra antitrombina beta que forma complejos con heparina
KR20230004939A (ko) * 2014-02-07 2023-01-06 맥마스터 유니버시티 3기능성 t 세포-항원 커플러 및 이의 제조 방법 및 용도
JP6913018B2 (ja) 2014-07-08 2021-08-04 ニューヨーク・ユニバーシティ タウイメージングリガンド、ならびにタウ異常症の診断および治療におけるそれらの使用
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
EP3334453A4 (en) 2015-08-13 2019-02-06 New York University ANTIBODY-BASED SPECIFIC MOLECULES AND THEIR USES IN THE DIAGNOSIS AND TREATMENT OF TAUOPATHY, FOR TAU'S SPECIFIC ASP421 EPITOP
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
JP7227630B2 (ja) 2017-10-12 2023-02-22 マックマスター ユニバーシティー Ｙ１８２ｔ突然変異を有するｔ細胞－抗原カプラおよびその方法ならびに使用
CN119241705A (zh) 2018-03-30 2025-01-03 安姆根有限公司 C末端抗体变体
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
US10640562B2 (en) 2018-07-17 2020-05-05 Mcmaster University T cell-antigen coupler with various construct optimizations
CN113621617B (zh) * 2020-04-21 2023-06-20 北京仁诚神经肿瘤生物技术工程研究中心有限公司 cDNA、mRNA、蛋白及评价胶质瘤预后性的试剂盒和系统
KR20240037892A (ko) 2021-06-01 2024-03-22 트리움비라 이뮤놀로직스 유에스에이, 인크. 클라우딘 18.2 t 세포-항원 커플러 및 이의 용도

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
DE3343530A1 (de) 1983-12-01 1985-06-13 Max Planck Gesellschaft Arzneimittel mit verbesserter penetration der gewebsmembran
US5474755A (en) 1984-01-31 1995-12-12 Akzo Nobel N.V. Tumor associated monoclonal antibodies
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4618477A (en) 1985-01-17 1986-10-21 International Business Machines Corporation Uniform plasma for drill smear removal reactor
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5017566A (en) 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
JPH01207920A (ja) 1988-02-16 1989-08-21 Oki Electric Ind Co Ltd ＩｎＰ半導体薄膜の製造方法
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
US5270202A (en) 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
JPH04346792A (ja) * 1991-05-22 1992-12-02 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体のアミノ酸配列及びそれをコードするｄｎａ塩基配列
WO1993007286A1 (en) 1991-09-30 1993-04-15 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Recombinant immunotoxins
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US5639863A (en) * 1994-06-21 1997-06-17 Dan; Michael D. Human monoclonal antibodies specific to cell cycle independent glioma surface antigen
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
KR20000015893A (ko) 1996-05-22 2000-03-15 댄 마이클 특이적으로 암세포를 검출하는 항원 결합 단편, 상기 단편을 코딩하는 뉴클레오티드 및 암의 예방 및 검출에 사용되는 이들의 용도

Similar Documents

Publication Publication Date Title
JP4124486B2 (ja) ガン細胞を特異的に検出する抗原結合フラグメント、このフラグメントをコードするヌクレオチド、ならびにガンの予防および検出のためのその使用
JP2000511421A5 (enExample)
JP4824025B2 (ja) トランスフェリンレセプター抗体
US7183384B2 (en) Monoclonal antibody 7H11 reactive with human cancer
JP3492373B2 (ja) モノクローナル抗体
PT94565B (pt) Novos anticorpos reactivos com carcinomas humanos
CA2928895C (en) Antibodies against ccr9 and applications thereof
JPH04502702A (ja) ヒト癌に対する新規なモノクローナル抗体
EP0521842A2 (en) Tumor antigen specific antibody
JP2001509369A (ja) ガン細胞を特異的に検出する４ｂ５と命名される抗原結合フラグメント、フラグメントをコードするヌクレオチド、ならびにガンの予防および検出のためのそれらの使用
US7560095B2 (en) Cancer specific monoclonal antibodies
US20080031873A1 (en) Humanized monoclonal antibody 31.1 as an anticancer agent
CA2255540C (en) Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
US7115722B1 (en) Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
AU775448B2 (en) Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
NZ505305A (en) Antigen binding fragments that inhibit an antibody comprising amino acid sequences of H and L chain V regions of a scFv from binding to the surface of a cancer cell
WO2001040292A1 (en) Antigen-binding fragments specific for tumor associated antigens
PL168720B1 (pl) Sposób wytwarzania nowego bispecyficznego przeciwciala BR 96 PL